Comparative Pharmacology
Head-to-head clinical analysis: CHOLOGRAFIN MEGLUMINE versus ULTRAVIST 300 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOGRAFIN MEGLUMINE versus ULTRAVIST 300 IN PLASTIC CONTAINER.
CHOLOGRAFIN MEGLUMINE vs ULTRAVIST 300 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholografin meglumine is an iodinated contrast agent that opacifies the biliary tract. It is actively taken up by hepatocytes and excreted into the bile, allowing radiographic visualization of the bile ducts and gallbladder.
Iopromide is a nonionic, low-osmolality iodinated contrast medium that attenuates X-rays due to its iodine content (300 mg iodine/mL). It provides radiographic contrast in vascular and parenchymal imaging by increasing the density of blood vessels and tissues, thereby enhancing the visibility of structures and lesions.
Intravenous: 20 mL (10.3 g) of a 52% solution (meglumine salt) administered by slow IV injection over 3-5 minutes; repeated once after 10-15 minutes if visualization is inadequate, not to exceed 40 mL total.
Intravenous administration of 1-2 mL/kg (300 mg iodine/mL) for contrast-enhanced CT; typical adult dose 100-150 mL (30-45 g iodine) given as bolus or rapid infusion.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic function, reflecting rapid biliary excretion; prolonged in hepatic impairment.
Terminal half-life: 2 hours in patients with normal renal function; prolonged up to 30 hours in severe renal impairment (CrCl <30 mL/min).
Primarily hepatic excretion via bile into feces; renal excretion accounts for <1% of the dose in patients with normal hepatic function.
Renal: 90% unchanged via glomerular filtration within 24 hours; biliary: <1%; fecal: <2%.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent